Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
blood plasma (1 trial)
COVID-19 convalescent plasma (1 trial)
cryoprecipitate (1 trial)
platelets (1 trial)
red blood cells (2 trials)
tranexamic acid (cyklokapron) (1 trial)
whole blood (1 trial)
autologous bone marrow derived mesenchymal cells (1 trial)
autologous mesenchymal stem cells (1 trial)
Diabetic Nephropathies (Phase 2)
Hematologic Neoplasms (Phase 3)
Hemorrhage (Phase 3)
Kidney Diseases (Phase 2)
Thrombocytopenia (Phase 3)
Trials (6 total)
Trial APIs (9 total)